| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shoulder Joint | 39 | 2022 | 110 | 10.840 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 17 | 2022 | 41 | 10.320 |
Why?
|
| Arthroplasty, Replacement, Knee | 32 | 2021 | 146 | 9.730 |
Why?
|
| Arthroplasty, Replacement, Hip | 25 | 2021 | 130 | 5.890 |
Why?
|
| Rotator Cuff Injuries | 7 | 2022 | 32 | 3.920 |
Why?
|
| Arthroplasty, Replacement | 12 | 2022 | 48 | 3.470 |
Why?
|
| Venous Thromboembolism | 17 | 2015 | 116 | 3.430 |
Why?
|
| Anticoagulants | 20 | 2015 | 356 | 3.000 |
Why?
|
| Knee Prosthesis | 15 | 2019 | 64 | 2.430 |
Why?
|
| Osteoarthritis | 10 | 2022 | 73 | 2.410 |
Why?
|
| Glenoid Cavity | 5 | 2021 | 12 | 2.380 |
Why?
|
| Joint Prosthesis | 16 | 2016 | 48 | 2.370 |
Why?
|
| Range of Motion, Articular | 20 | 2022 | 139 | 2.020 |
Why?
|
| Prosthesis Design | 15 | 2020 | 301 | 2.010 |
Why?
|
| Benzimidazoles | 9 | 2015 | 128 | 1.920 |
Why?
|
| Postoperative Complications | 26 | 2021 | 1615 | 1.830 |
Why?
|
| Blood Loss, Surgical | 6 | 2018 | 79 | 1.750 |
Why?
|
| Venous Thrombosis | 11 | 2015 | 124 | 1.730 |
Why?
|
| Shoulder Prosthesis | 3 | 2020 | 5 | 1.590 |
Why?
|
| Postoperative Hemorrhage | 3 | 2018 | 69 | 1.580 |
Why?
|
| Scapula | 9 | 2021 | 36 | 1.430 |
Why?
|
| Thromboembolism | 7 | 2018 | 91 | 1.380 |
Why?
|
| Treatment Outcome | 27 | 2022 | 7028 | 1.310 |
Why?
|
| Humans | 126 | 2022 | 68525 | 1.270 |
Why?
|
| Tranexamic Acid | 3 | 2018 | 37 | 1.260 |
Why?
|
| Retrospective Studies | 29 | 2022 | 7264 | 1.250 |
Why?
|
| Enoxaparin | 10 | 2014 | 51 | 1.240 |
Why?
|
| Rotator Cuff | 8 | 2022 | 25 | 1.170 |
Why?
|
| Pyridines | 5 | 2012 | 261 | 1.150 |
Why?
|
| Rotator Cuff Tear Arthropathy | 2 | 2022 | 4 | 1.070 |
Why?
|
| Pain, Postoperative | 6 | 2021 | 214 | 1.050 |
Why?
|
| Morpholines | 8 | 2015 | 79 | 1.050 |
Why?
|
| Thiophenes | 8 | 2015 | 76 | 1.040 |
Why?
|
| Obesity, Morbid | 2 | 2020 | 172 | 1.020 |
Why?
|
| Aged | 49 | 2022 | 14842 | 1.000 |
Why?
|
| Arthritis | 3 | 2022 | 53 | 1.000 |
Why?
|
| Blood Transfusion | 7 | 2018 | 205 | 0.970 |
Why?
|
| Osteoarthritis, Knee | 2 | 2021 | 26 | 0.960 |
Why?
|
| Orthopedic Procedures | 3 | 2011 | 102 | 0.940 |
Why?
|
| Polyethylene | 3 | 2019 | 31 | 0.890 |
Why?
|
| Middle Aged | 52 | 2022 | 21119 | 0.870 |
Why?
|
| Tissue Adhesives | 1 | 2022 | 17 | 0.860 |
Why?
|
| Biocompatible Materials | 10 | 2000 | 247 | 0.850 |
Why?
|
| Tibia | 4 | 2019 | 93 | 0.840 |
Why?
|
| Osteoarthritis, Hip | 1 | 2021 | 12 | 0.800 |
Why?
|
| Shoulder Pain | 2 | 2018 | 12 | 0.800 |
Why?
|
| Epidemics | 1 | 2021 | 12 | 0.800 |
Why?
|
| Fibrinolytic Agents | 4 | 2010 | 377 | 0.780 |
Why?
|
| beta-Alanine | 4 | 2015 | 20 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2011 | 503 | 0.740 |
Why?
|
| Organ Transplantation | 1 | 2021 | 110 | 0.700 |
Why?
|
| Shoulder Impingement Syndrome | 1 | 2019 | 5 | 0.690 |
Why?
|
| Patella | 1 | 2019 | 14 | 0.690 |
Why?
|
| Male | 63 | 2022 | 37281 | 0.690 |
Why?
|
| Dabigatran | 9 | 2015 | 35 | 0.690 |
Why?
|
| Metals | 2 | 2019 | 100 | 0.680 |
Why?
|
| Pulmonary Embolism | 7 | 2015 | 253 | 0.680 |
Why?
|
| Antifibrinolytic Agents | 2 | 2016 | 52 | 0.670 |
Why?
|
| Biomechanical Phenomena | 16 | 2018 | 368 | 0.670 |
Why?
|
| Knee Joint | 7 | 2019 | 115 | 0.670 |
Why?
|
| Bone Screws | 3 | 2019 | 90 | 0.660 |
Why?
|
| Hematologic Agents | 1 | 2018 | 11 | 0.650 |
Why?
|
| Joint Instability | 5 | 2020 | 87 | 0.650 |
Why?
|
| Surgical Wound Infection | 4 | 2014 | 168 | 0.650 |
Why?
|
| Heparin, Low-Molecular-Weight | 6 | 2010 | 41 | 0.650 |
Why?
|
| Humerus | 8 | 2017 | 23 | 0.640 |
Why?
|
| Pyridones | 3 | 2015 | 40 | 0.630 |
Why?
|
| Double-Blind Method | 7 | 2017 | 1737 | 0.600 |
Why?
|
| Arthroplasty | 4 | 2021 | 24 | 0.600 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 4843 | 0.590 |
Why?
|
| Female | 53 | 2020 | 38015 | 0.580 |
Why?
|
| Pyrazoles | 3 | 2015 | 190 | 0.580 |
Why?
|
| Databases, Factual | 7 | 2020 | 621 | 0.570 |
Why?
|
| Orthopedics | 5 | 2021 | 88 | 0.570 |
Why?
|
| Registries | 5 | 2018 | 730 | 0.560 |
Why?
|
| Reoperation | 7 | 2020 | 467 | 0.560 |
Why?
|
| Materials Testing | 8 | 2019 | 263 | 0.540 |
Why?
|
| Sex Factors | 5 | 2018 | 1265 | 0.540 |
Why?
|
| Hip Prosthesis | 7 | 1996 | 85 | 0.540 |
Why?
|
| Rivaroxaban | 8 | 2015 | 26 | 0.520 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2012 | 84 | 0.510 |
Why?
|
| Administration, Oral | 7 | 2015 | 411 | 0.510 |
Why?
|
| Age Factors | 4 | 2018 | 1860 | 0.500 |
Why?
|
| Thrombin | 3 | 2009 | 117 | 0.500 |
Why?
|
| Arthritis, Rheumatoid | 7 | 1998 | 155 | 0.500 |
Why?
|
| Aspirin | 3 | 2012 | 295 | 0.500 |
Why?
|
| Hemostasis, Surgical | 2 | 2010 | 18 | 0.490 |
Why?
|
| Osteonecrosis | 3 | 2021 | 20 | 0.480 |
Why?
|
| Prospective Studies | 13 | 2022 | 3702 | 0.470 |
Why?
|
| Shoulder | 6 | 2020 | 37 | 0.470 |
Why?
|
| Incidence | 7 | 2020 | 1582 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 5 | 2011 | 772 | 0.450 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 239 | 0.450 |
Why?
|
| Adult | 34 | 2020 | 21375 | 0.440 |
Why?
|
| Warfarin | 5 | 2011 | 93 | 0.440 |
Why?
|
| Arthroscopy | 5 | 2021 | 95 | 0.420 |
Why?
|
| Rotation | 4 | 2020 | 58 | 0.420 |
Why?
|
| Bacterial Adhesion | 5 | 1998 | 33 | 0.410 |
Why?
|
| Titanium | 4 | 1996 | 118 | 0.400 |
Why?
|
| Factor Xa Inhibitors | 4 | 2015 | 43 | 0.390 |
Why?
|
| Tourniquets | 4 | 2018 | 18 | 0.380 |
Why?
|
| Europe | 3 | 2020 | 195 | 0.370 |
Why?
|
| Prosthesis Failure | 6 | 2019 | 130 | 0.350 |
Why?
|
| Drug Design | 1 | 2009 | 107 | 0.340 |
Why?
|
| Fractures, Bone | 3 | 2020 | 132 | 0.340 |
Why?
|
| Elective Surgical Procedures | 4 | 2015 | 95 | 0.340 |
Why?
|
| Hemorrhage | 6 | 2015 | 328 | 0.340 |
Why?
|
| Femur | 4 | 1998 | 113 | 0.330 |
Why?
|
| Hip Fractures | 1 | 2008 | 26 | 0.330 |
Why?
|
| Osteolysis | 3 | 2019 | 15 | 0.320 |
Why?
|
| Guideline Adherence | 2 | 2008 | 284 | 0.320 |
Why?
|
| Time Factors | 13 | 2019 | 4655 | 0.320 |
Why?
|
| Obesity | 3 | 2021 | 1074 | 0.300 |
Why?
|
| Body Mass Index | 3 | 2020 | 866 | 0.300 |
Why?
|
| Embolism | 1 | 2007 | 45 | 0.300 |
Why?
|
| Drug Administration Schedule | 6 | 2015 | 567 | 0.290 |
Why?
|
| United States | 8 | 2020 | 7335 | 0.290 |
Why?
|
| Humeral Head | 3 | 2021 | 9 | 0.290 |
Why?
|
| Prostheses and Implants | 3 | 2017 | 159 | 0.270 |
Why?
|
| Radiography | 11 | 2020 | 572 | 0.270 |
Why?
|
| Prednisone | 2 | 1995 | 104 | 0.260 |
Why?
|
| Osseointegration | 4 | 1998 | 19 | 0.260 |
Why?
|
| Pain | 6 | 2022 | 472 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 2222 | 0.260 |
Why?
|
| Bone and Bones | 3 | 1996 | 145 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2014 | 929 | 0.240 |
Why?
|
| Risk Factors | 10 | 2015 | 5719 | 0.240 |
Why?
|
| Physicians | 1 | 2008 | 324 | 0.240 |
Why?
|
| Stress, Physiological | 2 | 1995 | 215 | 0.240 |
Why?
|
| Glucocorticoids | 2 | 1995 | 222 | 0.230 |
Why?
|
| Absorbable Implants | 2 | 2000 | 29 | 0.230 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 3256 | 0.230 |
Why?
|
| Antithrombins | 2 | 2015 | 32 | 0.230 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 2077 | 0.220 |
Why?
|
| Cyanoacrylates | 1 | 2022 | 8 | 0.220 |
Why?
|
| Sutures | 1 | 2022 | 32 | 0.210 |
Why?
|
| Stress, Mechanical | 4 | 2015 | 208 | 0.210 |
Why?
|
| Clavicle | 3 | 2020 | 20 | 0.210 |
Why?
|
| Femur Head Necrosis | 3 | 1992 | 7 | 0.210 |
Why?
|
| Suture Techniques | 1 | 2022 | 75 | 0.210 |
Why?
|
| Arthroplasty, Replacement, Elbow | 1 | 2021 | 2 | 0.210 |
Why?
|
| Elbow | 1 | 2021 | 6 | 0.210 |
Why?
|
| Elbow Joint | 3 | 1999 | 14 | 0.210 |
Why?
|
| Thrombosis | 1 | 2003 | 218 | 0.200 |
Why?
|
| Fractures, Comminuted | 1 | 2020 | 4 | 0.200 |
Why?
|
| Arthrography | 1 | 2020 | 13 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2014 | 2004 | 0.190 |
Why?
|
| Patient Positioning | 1 | 2020 | 15 | 0.190 |
Why?
|
| Cefazolin | 2 | 1990 | 19 | 0.190 |
Why?
|
| Suction | 2 | 2018 | 33 | 0.190 |
Why?
|
| Demography | 1 | 2021 | 279 | 0.190 |
Why?
|
| Coracoid Process | 1 | 2019 | 2 | 0.180 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2020 | 8 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 2 | 1996 | 364 | 0.180 |
Why?
|
| Recovery of Function | 3 | 2018 | 506 | 0.180 |
Why?
|
| Sepsis | 2 | 1996 | 233 | 0.180 |
Why?
|
| Health Planning Guidelines | 2 | 2010 | 23 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2021 | 333 | 0.180 |
Why?
|
| Activities of Daily Living | 2 | 2020 | 319 | 0.170 |
Why?
|
| Thrombophlebitis | 2 | 1997 | 47 | 0.170 |
Why?
|
| Epoetin Alfa | 2 | 2018 | 23 | 0.170 |
Why?
|
| Tendons | 2 | 2017 | 45 | 0.170 |
Why?
|
| Rabbits | 6 | 1998 | 509 | 0.170 |
Why?
|
| Joint Diseases | 3 | 1999 | 37 | 0.170 |
Why?
|
| Shoulder Fractures | 1 | 1998 | 5 | 0.170 |
Why?
|
| Software | 1 | 2021 | 418 | 0.170 |
Why?
|
| Weight-Bearing | 2 | 1998 | 53 | 0.170 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2018 | 17 | 0.160 |
Why?
|
| Hemiarthroplasty | 1 | 2018 | 7 | 0.160 |
Why?
|
| Length of Stay | 3 | 2021 | 780 | 0.160 |
Why?
|
| Prosthesis-Related Infections | 2 | 1996 | 70 | 0.160 |
Why?
|
| Nerve Block | 2 | 2000 | 55 | 0.160 |
Why?
|
| Freezing | 1 | 1997 | 29 | 0.160 |
Why?
|
| Injections, Subcutaneous | 4 | 2011 | 87 | 0.150 |
Why?
|
| Infection Control | 2 | 1996 | 101 | 0.150 |
Why?
|
| Tendinopathy | 1 | 2017 | 5 | 0.150 |
Why?
|
| Erythema | 1 | 2017 | 18 | 0.150 |
Why?
|
| Adolescent | 8 | 2020 | 8903 | 0.150 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1997 | 25 | 0.150 |
Why?
|
| Cryopreservation | 1 | 1997 | 103 | 0.150 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2017 | 52 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 438 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 378 | 0.150 |
Why?
|
| Standard of Care | 1 | 2016 | 22 | 0.150 |
Why?
|
| Michigan | 1 | 2016 | 68 | 0.150 |
Why?
|
| Cattle | 1 | 1997 | 475 | 0.140 |
Why?
|
| Linear Models | 1 | 2018 | 521 | 0.140 |
Why?
|
| Serum Albumin | 1 | 1996 | 104 | 0.140 |
Why?
|
| Cross-Linking Reagents | 1 | 1996 | 80 | 0.140 |
Why?
|
| Ketones | 1 | 1996 | 24 | 0.140 |
Why?
|
| Durapatite | 2 | 1998 | 33 | 0.140 |
Why?
|
| Adrenal Insufficiency | 1 | 1995 | 10 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2020 | 2356 | 0.140 |
Why?
|
| Tetrazolium Salts | 1 | 1995 | 36 | 0.130 |
Why?
|
| Staphylococcus | 1 | 1995 | 29 | 0.130 |
Why?
|
| Musculoskeletal Diseases | 1 | 1995 | 45 | 0.130 |
Why?
|
| Osteotomy | 4 | 1998 | 46 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 1995 | 144 | 0.130 |
Why?
|
| Colony Count, Microbial | 1 | 1995 | 77 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 1996 | 149 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 334 | 0.130 |
Why?
|
| Joint Dislocations | 2 | 2020 | 40 | 0.130 |
Why?
|
| Chromium Alloys | 1 | 1995 | 16 | 0.130 |
Why?
|
| Carbon | 1 | 1996 | 122 | 0.130 |
Why?
|
| Contracture | 1 | 1994 | 15 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2012 | 289 | 0.130 |
Why?
|
| Etidocaine | 1 | 1994 | 1 | 0.120 |
Why?
|
| Primary Prevention | 2 | 2009 | 115 | 0.120 |
Why?
|
| Brachial Plexus | 1 | 1994 | 15 | 0.120 |
Why?
|
| Steroids | 1 | 1995 | 84 | 0.120 |
Why?
|
| Postoperative Period | 2 | 2013 | 238 | 0.120 |
Why?
|
| Bupivacaine | 1 | 1994 | 27 | 0.120 |
Why?
|
| Analgesia | 1 | 1994 | 58 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 2323 | 0.110 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1992 | 17 | 0.110 |
Why?
|
| Fractures, Closed | 2 | 1994 | 6 | 0.110 |
Why?
|
| Arthritis, Gouty | 1 | 1992 | 2 | 0.110 |
Why?
|
| Young Adult | 3 | 2020 | 5708 | 0.110 |
Why?
|
| Quality of Life | 2 | 2020 | 1515 | 0.110 |
Why?
|
| Animals | 13 | 2017 | 20877 | 0.110 |
Why?
|
| Spine | 1 | 1992 | 46 | 0.110 |
Why?
|
| Clinical Trials as Topic | 4 | 2000 | 848 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 1992 | 40 | 0.110 |
Why?
|
| Fracture Fixation, Internal | 3 | 2020 | 68 | 0.110 |
Why?
|
| Intraoperative Period | 2 | 2010 | 62 | 0.100 |
Why?
|
| Ethics, Medical | 1 | 1992 | 86 | 0.100 |
Why?
|
| Research Design | 3 | 2010 | 729 | 0.100 |
Why?
|
| Antithrombin Proteins | 1 | 2011 | 1 | 0.100 |
Why?
|
| Research | 1 | 1992 | 214 | 0.100 |
Why?
|
| Surface Properties | 3 | 1998 | 363 | 0.100 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2010 | 6 | 0.100 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.100 |
Why?
|
| Cost Savings | 1 | 2011 | 110 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 648 | 0.090 |
Why?
|
| Fractures, Ununited | 1 | 1990 | 16 | 0.090 |
Why?
|
| Connective Tissue | 1 | 1990 | 61 | 0.090 |
Why?
|
| Hip Dislocation | 1 | 1989 | 8 | 0.090 |
Why?
|
| Compartment Syndromes | 1 | 1989 | 13 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 373 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2011 | 403 | 0.090 |
Why?
|
| Wit and Humor as Topic | 1 | 1989 | 6 | 0.090 |
Why?
|
| Sternoclavicular Joint | 1 | 1989 | 3 | 0.090 |
Why?
|
| Blood Coagulation | 1 | 2009 | 123 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.080 |
Why?
|
| Costs and Cost Analysis | 2 | 2000 | 193 | 0.080 |
Why?
|
| Medicine | 1 | 1989 | 51 | 0.080 |
Why?
|
| Bone Plates | 2 | 2020 | 49 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2011 | 346 | 0.080 |
Why?
|
| Electric Stimulation Therapy | 1 | 1990 | 147 | 0.080 |
Why?
|
| Indium Radioisotopes | 1 | 1988 | 19 | 0.080 |
Why?
|
| Prognosis | 4 | 1999 | 2093 | 0.080 |
Why?
|
| Escherichia coli Infections | 1 | 1988 | 47 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 880 | 0.080 |
Why?
|
| Postoperative Care | 2 | 1999 | 163 | 0.080 |
Why?
|
| Pain Measurement | 3 | 2017 | 328 | 0.080 |
Why?
|
| Catheterization, Peripheral | 1 | 1988 | 38 | 0.080 |
Why?
|
| Exercise Therapy | 2 | 2000 | 183 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 57 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 1995 | 839 | 0.070 |
Why?
|
| Physical Examination | 2 | 2000 | 152 | 0.070 |
Why?
|
| Neoplasms | 2 | 2015 | 1660 | 0.070 |
Why?
|
| Dogs | 3 | 1998 | 490 | 0.070 |
Why?
|
| Melanoma | 3 | 1996 | 335 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 1996 | 236 | 0.070 |
Why?
|
| International Normalized Ratio | 1 | 2005 | 23 | 0.070 |
Why?
|
| Skin Neoplasms | 3 | 1996 | 375 | 0.070 |
Why?
|
| Movement | 3 | 1995 | 179 | 0.070 |
Why?
|
| Porosity | 2 | 1998 | 63 | 0.070 |
Why?
|
| Temperature | 2 | 1997 | 340 | 0.070 |
Why?
|
| Polymers | 2 | 1998 | 244 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 2 | 1996 | 261 | 0.060 |
Why?
|
| Population Surveillance | 3 | 2011 | 285 | 0.060 |
Why?
|
| Clinical Protocols | 2 | 1998 | 172 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 2 | 1995 | 124 | 0.060 |
Why?
|
| Erythropoietin | 2 | 1996 | 96 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1753 | 0.060 |
Why?
|
| Observer Variation | 2 | 2017 | 330 | 0.060 |
Why?
|
| Probability | 2 | 2005 | 244 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 1995 | 291 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 1745 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 442 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 1996 | 1039 | 0.050 |
Why?
|
| Bone Diseases, Metabolic | 2 | 1998 | 30 | 0.050 |
Why?
|
| Cryotherapy | 1 | 2021 | 36 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 1998 | 2550 | 0.050 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2000 | 3 | 0.050 |
Why?
|
| Torque | 1 | 2019 | 33 | 0.050 |
Why?
|
| Models, Anatomic | 1 | 2019 | 51 | 0.050 |
Why?
|
| Decision Trees | 1 | 2000 | 74 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 1046 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 265 | 0.040 |
Why?
|
| Medical Records | 1 | 1999 | 121 | 0.040 |
Why?
|
| Polyglycolic Acid | 1 | 1998 | 20 | 0.040 |
Why?
|
| Consumer Behavior | 2 | 1989 | 68 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 1997 | 765 | 0.040 |
Why?
|
| Stainless Steel | 1 | 1998 | 31 | 0.040 |
Why?
|
| Motion Pictures | 1 | 1998 | 8 | 0.040 |
Why?
|
| Femoral Fractures | 1 | 1998 | 45 | 0.040 |
Why?
|
| Bone Cements | 1 | 1998 | 39 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 1998 | 108 | 0.040 |
Why?
|
| Lactic Acid | 1 | 1998 | 86 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2000 | 191 | 0.040 |
Why?
|
| Cricetinae | 1 | 1998 | 262 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 1998 | 210 | 0.040 |
Why?
|
| Biofilms | 1 | 1998 | 72 | 0.040 |
Why?
|
| Osteoporosis | 1 | 1998 | 88 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1998 | 186 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 1996 | 9 | 0.040 |
Why?
|
| Information Systems | 1 | 1996 | 45 | 0.040 |
Why?
|
| Case Management | 1 | 1997 | 46 | 0.040 |
Why?
|
| Preoperative Care | 2 | 1996 | 275 | 0.040 |
Why?
|
| Acute Disease | 1 | 1998 | 658 | 0.040 |
Why?
|
| Benzophenones | 1 | 1996 | 12 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 1998 | 163 | 0.040 |
Why?
|
| Chromium | 1 | 1996 | 26 | 0.040 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1996 | 21 | 0.040 |
Why?
|
| Cobalt | 1 | 1996 | 37 | 0.040 |
Why?
|
| Adrenal Cortex Function Tests | 1 | 1995 | 1 | 0.030 |
Why?
|
| Equipment Contamination | 1 | 1996 | 38 | 0.030 |
Why?
|
| France | 1 | 2015 | 26 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 1996 | 84 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1998 | 311 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1995 | 94 | 0.030 |
Why?
|
| Arthralgia | 1 | 1996 | 30 | 0.030 |
Why?
|
| Hematinics | 1 | 1996 | 52 | 0.030 |
Why?
|
| Eosinophils | 1 | 1995 | 60 | 0.030 |
Why?
|
| Propidium | 1 | 1995 | 26 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2017 | 298 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 1995 | 43 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 219 | 0.030 |
Why?
|
| Bisbenzimidazole | 1 | 1995 | 13 | 0.030 |
Why?
|
| Sodium | 1 | 1995 | 161 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 396 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 742 | 0.030 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 1994 | 6 | 0.030 |
Why?
|
| Creatinine | 1 | 1995 | 243 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 1995 | 258 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 1995 | 191 | 0.030 |
Why?
|
| Tibial Fractures | 1 | 1994 | 25 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 1329 | 0.030 |
Why?
|
| Hypotension, Controlled | 1 | 1992 | 1 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 1995 | 201 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 1996 | 384 | 0.030 |
Why?
|
| Human Experimentation | 1 | 1992 | 19 | 0.030 |
Why?
|
| Hemoglobin SC Disease | 1 | 1992 | 7 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 1992 | 91 | 0.030 |
Why?
|
| International Cooperation | 1 | 1992 | 88 | 0.030 |
Why?
|
| Equipment Design | 1 | 1994 | 500 | 0.030 |
Why?
|
| Sickle Cell Trait | 1 | 1992 | 24 | 0.030 |
Why?
|
| Hydroxyapatites | 1 | 1992 | 10 | 0.030 |
Why?
|
| Stockings, Compression | 1 | 2011 | 9 | 0.030 |
Why?
|
| Survival Rate | 3 | 2005 | 1055 | 0.030 |
Why?
|
| Ceramics | 1 | 1992 | 23 | 0.030 |
Why?
|
| Research Personnel | 1 | 1992 | 83 | 0.030 |
Why?
|
| Quality Control | 1 | 1992 | 81 | 0.030 |
Why?
|
| Motion Therapy, Continuous Passive | 1 | 1991 | 1 | 0.030 |
Why?
|
| Growth Substances | 1 | 1992 | 77 | 0.030 |
Why?
|
| Anesthesia, Epidural | 1 | 1991 | 11 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 1992 | 45 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 1992 | 125 | 0.030 |
Why?
|
| Hematocrit | 1 | 1991 | 70 | 0.030 |
Why?
|
| Ossification, Heterotopic | 1 | 1992 | 45 | 0.030 |
Why?
|
| Indomethacin | 1 | 1992 | 107 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 219 | 0.020 |
Why?
|
| Informed Consent | 1 | 1992 | 127 | 0.020 |
Why?
|
| Reference Values | 1 | 1992 | 579 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2011 | 107 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 1026 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 1991 | 86 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 592 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1990 | 282 | 0.020 |
Why?
|
| Locomotion | 1 | 1990 | 135 | 0.020 |
Why?
|
| Random Allocation | 1 | 1990 | 442 | 0.020 |
Why?
|
| Manipulation, Orthopedic | 1 | 1989 | 5 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 714 | 0.020 |
Why?
|
| Azetidines | 1 | 2008 | 6 | 0.020 |
Why?
|
| Benzylamines | 1 | 2008 | 28 | 0.020 |
Why?
|
| Osteogenesis | 1 | 1990 | 152 | 0.020 |
Why?
|
| North America | 1 | 2008 | 111 | 0.020 |
Why?
|
| Embolism, Fat | 1 | 1988 | 13 | 0.020 |
Why?
|
| Femur Head | 1 | 1988 | 17 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 1988 | 95 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 166 | 0.020 |
Why?
|
| Leukocytes | 1 | 1988 | 99 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1992 | 657 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1988 | 503 | 0.020 |
Why?
|
| Fracture Healing | 2 | 1998 | 29 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2008 | 176 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1988 | 156 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 306 | 0.020 |
Why?
|
| Health Services Research | 1 | 2005 | 209 | 0.020 |
Why?
|
| Child | 1 | 1995 | 6400 | 0.010 |
Why?
|
| Neural Conduction | 1 | 2000 | 24 | 0.010 |
Why?
|
| Arthritis, Juvenile | 1 | 2000 | 70 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1851 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 766 | 0.010 |
Why?
|
| Carrageenan | 1 | 1998 | 7 | 0.010 |
Why?
|
| Excipients | 1 | 1998 | 8 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 1998 | 23 | 0.010 |
Why?
|
| Tensile Strength | 1 | 1998 | 90 | 0.010 |
Why?
|
| Hemoglobinometry | 1 | 1996 | 5 | 0.010 |
Why?
|
| SEER Program | 1 | 1996 | 150 | 0.010 |
Why?
|
| Forecasting | 1 | 1996 | 277 | 0.010 |
Why?
|
| Life Tables | 1 | 1994 | 29 | 0.010 |
Why?
|
| Education, Medical | 1 | 1996 | 147 | 0.010 |
Why?
|
| New York | 1 | 1994 | 223 | 0.010 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1994 | 33 | 0.010 |
Why?
|
| Shoulder Injuries | 1 | 1993 | 5 | 0.010 |
Why?
|
| Health Education | 1 | 1996 | 279 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 369 | 0.010 |
Why?
|
| Biopsy | 1 | 1994 | 539 | 0.010 |
Why?
|
| Health Behavior | 1 | 1996 | 458 | 0.010 |
Why?
|
| Cadaver | 1 | 1991 | 136 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1999 | 2798 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1994 | 1548 | 0.010 |
Why?
|
| Joint Loose Bodies | 1 | 1990 | 4 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1992 | 799 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 2083 | 0.010 |
Why?
|
| Rats | 1 | 1994 | 5300 | 0.000 |
Why?
|